4-Amino-3-Chlorophenol CAS 17609-80-2 Lenvatinib Mesylate Intermediate Purity >99.0% (HPLC)
I-Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
I-Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
I-Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
I-Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
I-Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
I-4-Amino-3-Chlorophenol CAS 17609-80-2
I-4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
I-Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igama Lekhemikhali | 4-Amino-3-Chlorophenol |
Omqondofana | 3-Chloro-4-Aminophenol;Lenvaint-G |
Inombolo ye-CAS | 17609-80-2 |
Inombolo yeCAT | I-RF-PI1968 |
Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
I-Molecular Formula | I-C6H6ClNO |
Isisindo samangqamuzana | 143.57 |
Ukuminyana | 1.406±0.060 g/cm3 |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | I-Brown Solid Powder |
1 H NMR Spectrum | Ihambisana Nesakhiwo |
Identification-HPLC | Isikhathi sokugcina sifana nejwayelekile |
Ukuhlanzeka / Indlela Yokuhlaziya | >99.0% (HPLC) |
I-Melting Point | 138.0~141.0℃ |
Ukulahlekelwa Ekumisweni | <1.00% |
Izinsalela ekushiseni | <0.30% |
Ukungcola Okuphelele | <1.00% |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | I-Intermediate ye-Lenvatinib Mesylate (CAS: 857890-39-2) |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-4-Amino-3-Chlorophenol (i-CAS: 17609-80-2) iyindawo ebalulekile yemithi, esetshenziswa kabanzi ekwakhiweni nasekuhlanganiseni kwe-anti-tumor, izifo zenhliziyo, izifo ze-neurological.I-4-Amino-3-Chlorophenol iyingxenye ebalulekile yokulungiswa kwe-Lenvatinib Mesylate (CAS: 857890-39-2).Ithuthukiswe ngabakwa-Eisai Inc., i-lenvatinib mesylate iyi-vascular endothelial growth factor receptor (VEGF) inhibitor enomsebenzi omelene ne-VEGF subtypes 1, 2, no-3 futhi yagunyazwa yi-FDA ngo-2015 ukuze zelashwe umdlavuza wegilo ohlukile otholakala endaweni. ukuphindaphinda, i-metastatic, noma ukuqhubeka futhi ayizange iphendule ekwelashweni kwe-iodine enemisebe.NgoMeyi 2016, i-FDA yagunyaza umuthi njengendlela yokwelapha eyinhlanganisela ne-everolimus yokwelapha i-advanced renal cell carcinoma.Ngenxa yokuthi i-VEGF (kanye ne-fibroblast growth factor receptors, eyaziwa ngokuthi ama-FGFR) kucatshangwa ukuthi idlala indima emizileni yokubonisa izimpawu zenhliziyo, ukuvimbela i-VEGF2R kanye ne-FGFR kucatshangwa ukuthi yizinqubo ezingemuva komphumela oyinhloko we-lenvatinib mesylate, okuwumfutho wegazi ophezulu.